Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7044265 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL14280811 | 0.97 | ALDH1A1 (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5589752 | 0.97 | ALDH1A1 (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5589661 | 0.95 | ALDH1A1 (0.38) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL23982608 | 0.89 | RAB9A (0.38) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL25647091 | 0.87 | ALDH1A1 (0.35) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL21078305 | 0.87 | RAB9A (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL25940738 | 0.87 | MEN1 (0.34) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL5590682 | 0.86 | GRIN2D (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL14280799 | 0.86 | GRIN2D (0.39) | ALDH1A1KMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030104929-A1 | Polymerisation catalyst | BP CHEMICALS LIMITED (GB) | 2003-06-05 | — | — | US | claimed |
| EP-1216254-A1 | POLYMERISATION CATALYST | BP Chemicals Limited (GB) | 2002-06-26 | — | — | EP | claimed |
| WO-2001023396-A1 | POLYMERISATION CATALYST | BP CHEMICALS LIMITED (GB) | 2001-04-05 | — | — | WO | claimed |
| US-20030104929-A1 | Polymerisation catalyst | BP CHEMICALS LIMITED (GB) | 2003-06-05 | — | — | US | disclosed |
| EP-1216254-A1 | POLYMERISATION CATALYST | BP Chemicals Limited (GB) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023396-A1 | POLYMERISATION CATALYST | BP CHEMICALS LIMITED (GB) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104929-A1 | Polymerisation catalyst | RUVBL2, RUVBL1, MT-ND4L | ALDH1A1 4084/4885KMT2A 1611/4885SMN1; SMN2 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.